Rx Oversight Issues at Federal Workers’ Comp Program Endangered Patients, Audit Says
OWCP says that hiring a PBM will address overprescribing and cost concerns, but a consultant who participated in the audit is skeptical.
You may also be interested in...
Vigorous regulatory scrutiny is a given, but opinions vary about how much the companies’ respective PBM businesses present a major antitrust risk.
As legislation moves forward in Congress, an examination of high-utilization Part D-covered generic drugs concludes that other payers in the supply chain make almost as much money from spread pricing as PBMs do.
New coalition of smaller PBMs champions federal policies requiring ‘100% pass-through’ of rebates, with PBMs then paid by a flat, disclosed fee.